Other PROGRAMS

Idera’s chemistry-based approach to identify TLR-targeted compounds has generated a broad pipeline of candidates for the treatment of diverse diseases. Idera is focusing its internal development efforts on TLR-targeted compounds for autoimmune and inflammatory diseases and cancer, and on advancement of its GSO technology. Idera is collaborating with Merck & Co. for use of agonists of TLR7, 8 and 9 as vaccine adjuvants. Idera seeks to further advance TLR-targeted programs in infectious diseases, respiratory diseases, hematologic oncology and additional vaccine adjuvant applications through partnership with third parties.

Hematologic Oncology – IMO-4200

IMO-4200, a dual agonist of TLR7 and TLR8, is a lead drug candidate for the treatment of hematologic oncology.

Treatment with IMO-4200 in combination with approved cancer therapy agents such as the anti CD20 antibody rituximab or the proteosome inhibitor bortezomib has shown improved antitumor activity and increased survival in preclinical models of Non Hodgkin’s lymphoma. [Press Release]. The therapeutic effect of IMO-4200 on lymphoma is currently being further evaluated in combination studies with the anti-CD20 antibody ofatumumab or with rituximab and bendamustine or rituximab and fludarabine.

Presentations

Antitumor Activity of an RNA-Based Agonist of TLR7 and 8 in Preclinical Models of Hematological Malignancies at the 52nd Annual Meeting of the American Society of Hematology, December 2010
IMO-4200, a Novel TLR7 and TLR8 Dual Agonist, Enhances Antitumor Effect of Ofatumumab, Rituximab and Cytotoxics in Preclinical Models of Hematological Malignancies at the 53nd Annual Meeting of the American Society of Hematology, December 2011

TLR3 Agonists as Vaccine Adjuvants

Idera has created a new class of synthetic double-stranded RNA-based compounds that act as specific TLR3 agonists. Idera’s proprietary TLR3 agonists showed potent activity when used as a vaccine adjuvant in preclinical studies. Idera is continuing to evaluate the adjuvant activity of these compounds in preclinical models.

Respiratory Diseases – IMO-2134

IMO-2134, a TLR9 agonist, is a lead candidate for development in asthma and allergy indications. Asthma and allergy conditions are characterized by a Th1/Th2 imbalance in the immune system. Currently approved agents for the treatment of asthma and allergy, including steroids and antibodies, are designed to suppress symptoms of allergic or asthmatic response.

Idera has created a novel agonist of TLR9, IMO-2134, through its chemistry-based approach to making TLR-targeted compounds. IMO-2134 has shown to induce Th1 type immune responses, and has shown encouraging results in preclinical models of allergic asthma, including in non-human primate, of allergies. A Phase 1 clinical trial of IMO-2134 has been conducted in healthy subjects to evaluate safety and biomarkers of immune activation.

Clinical Trials of IMO-2134

A Phase 1 trial of IMO-2134 in healthy subjects [Press Release]